We present a case of Mobitz type II atrioventricular block during one-lung ventilation in a 74-year-old man with lung cancer under anesthesia. Premedication with atropine 0.5 mg and midazolam 2 mg intramuscularly were given 30 min before entering the operating room. Before anesthesia, his heart rate was 72 beats x min(-1) with normal sinus rhythm and blood pressure was 120/70 mmHg. An epidural catheter was placed at T4-5 interspace and 1.5% mepivacaine was infused (7 ml bolus and 5 ml x hr(-1) thereafter). After placing external pacemaker paddle, general anesthesia was induced with propofol 3 microg x ml(-1) and fentanyl 0.1 mg, and tracheal intubation was facilitated with vecuronium 6 mg. Anesthesia was maintained with propofol and fentanyl. After initiating one-lung ventilation, the patient developed Mobitz type II block with a heart rate of 30 beats x min(-1). External pacing was started (rate: 80 beats x min(-1), output: 150 mA). However, body movement associated with external pacing interrupted operative procedure, and blood pressure was not restored effectively. Therefore, external pacing was stopped and atropine and dopamine were administered. Mobitz type II block continued, but blood pressure and heart rate were maintained during the operation. Cardiac rhythm was restored the next morning without any treatment. Propofol, fentanyl, and thoracic epidural anesthesia could caused Mobitz type II block. External pacing should not be used for thoracic surgeries.
Download full-text PDF |
Source |
---|
Pol J Radiol
December 2024
First Hospital of Shanxi Medical University, Shanxi, China.
Purpose: Isocitrate dehydrogenase (IDH) mutation status serves as a crucial prognostic indicator for glioma, typically assessed via immunohistochemical analysis post-surgery. Given the invasiveness of this approach, perhaps we can utilise convenient and noninvasive magnetic resonance imaging (MRI) methods to predict IDH mutation status. However, the current landscape lacks a standardised MRI technique for accurately predicting IDH mutations.
View Article and Find Full Text PDFJ Bone Miner Res
January 2025
Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada.
Timelapse imaging using high-resolution peripheral quantitative computed tomography (HR-pQCT) has emerged as a noninvasive method to quantify bone (re)modelling. However, there is no consensus on how to perform the procedure. As part of the ASTEROID phase-2b multicenter trial, we used 29 same-day repeated scans from adults with osteogenesis imperfecta (OI) to identify a method that minimized measurement error.
View Article and Find Full Text PDFJ Neural Transm (Vienna)
January 2025
Institut für Zellbiochemie, OE 4310, Medizinische Hochschule Hannover, 30623, Hannover, Germany.
Botulinum neurotoxins (BoNT) are established biopharmaceuticals for neuromuscular and secretory conditions based on their ability to block neurotransmitter release from neurons by proteolyzing specific soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. Recently, a mutant catalytic domain of serotype E (LC/E) exhibiting 16 mutations was reported to cleave the phosphatase and tensin homolog (PTEN). This molecule represents an attractive new target in neurons as several reports support PTEN knockdown as a strategy to stimulate axonal regeneration after injury.
View Article and Find Full Text PDFCardiovasc Intervent Radiol
January 2025
Department of Diagnostic Imaging, Interventional Radiology, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, CABA, CP C1199ABB, Buenos Aires, Argentina.
Lancet Diabetes Endocrinol
January 2025
Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Electronic address:
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!